Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Humacyte, Inc.HUMA · Entity 6478 | Director | October 06, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Humacyte, Inc.
Report date October 06, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.48 · Expires 2036-10-06 | Direct | 125,000 |
Reported balance
After 2026-10-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 125,000 · Balance 125,000 F1: The first 25% of the option becomes exercisable on October 6, 2027, after which 1/48 of the option becomes exercisable on the 6th day of each month thereafter, with the option becoming fully vested on October 6, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: The first 25% of the option becomes exercisable on October 6, 2027, after which 1/48 of the option becomes exercisable on the 6th day of each month thereafter, with the option becoming fully vested on October 6, 2030.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EXACT SCIENCES CORP
Report date March 23, 2026 · Filed March 23, 2026
Section 16 reporting ended · disclosed 2026-03-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-03-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-23 · Disposition to issuer · Disposed 52,164 · Balance 5,398 F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration"). Row 2 · 2026-03-23 · Disposition to issuer · Disposed 5,398 · Balance 0 F2: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding. |
| Common StockSEC Table I · non-derivative | IndirectHeld in 401(k) Plan | 0 |
Reported balance
After 2026-03-23 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-03-23 · Disposition to issuer · Disposed 4,694 · Balance 0 F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration"). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.37 | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-23 · Disposition to issuer · Disposed 4,175 · Balance 0 F4: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F3: These options became exercisable on February 27, 2022. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $92.62 | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-23 · Disposition to issuer · Disposed 10,786 · Balance 0 F4: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F5: These options became exercisable on February 26, 2023. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $98.18 | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-23 · Disposition to issuer · Disposed 12,875 · Balance 0 F4: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F6: These options became exercisable on February 14, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").
F2: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.
F3: These options became exercisable on February 27, 2022.
F4: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
F5: These options became exercisable on February 26, 2023.
F6: These options became exercisable on February 14, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 7, 2026 20:06 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001247296-26-000005 · ownership.xml · derivative · entry 1 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2036-10-06 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on October 6, 2027, after which 1/48 of the option becomes exercisable on the 6th day of each month thereafter, with the option becoming fully vested on October 6, 2030. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerStock Options (Right to Buy) · Derivative | 12,875 | Not disclosed Strike: $98.18 | Not disclosed |
DisclosureSEC source: 0001193125-26-118752 · ownership.xml · derivative · entry 6 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,875 shares Expires not disclosed F4 · price: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F6 · derivative.exercise_date: These options became exercisable on February 14, 2024. F6 · derivative.expiration_date: These options became exercisable on February 14, 2024. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerStock Options (Right to Buy) · Derivative | 10,786 | Not disclosed Strike: $92.62 | Not disclosed |
DisclosureSEC source: 0001193125-26-118752 · ownership.xml · derivative · entry 5 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,786 shares Expires not disclosed F4 · price: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F5 · derivative.exercise_date: These options became exercisable on February 26, 2023. F5 · derivative.expiration_date: These options became exercisable on February 26, 2023. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerStock Options (Right to Buy) · Derivative | 4,175 | Not disclosed Strike: $44.37 | Not disclosed |
DisclosureSEC source: 0001193125-26-118752 · ownership.xml · derivative · entry 4 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,175 shares Expires not disclosed F4 · price: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F3 · derivative.exercise_date: These options became exercisable on February 27, 2022. F3 · derivative.expiration_date: These options became exercisable on February 27, 2022. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerCommon Stock | 4,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118752 · ownership.xml · nonDerivative · entry 3 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held in 401(k) Plan Disclosed balance after: 0 F1 · price: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration"). Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerCommon Stock | 5,398 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118752 · ownership.xml · nonDerivative · entry 2 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerCommon Stock | 52,164 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118752 · ownership.xml · nonDerivative · entry 1 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,398 F1 · price: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration"). Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 17:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 5,398 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-086883 · ownership.xml · nonDerivative · entry 1 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,562 F1 · shares: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 2,248 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-024895 · ownership.xml · derivative · entry 4 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Represents a restricted stock unit award granted on February 19, 2021 that vests in four equal annual installments from the grant date. F4 · derivative.expiration_date: Represents a restricted stock unit award granted on February 19, 2021 that vests in four equal annual installments from the grant date. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 667 | $49.63 | $33,103.21 |
DisclosureSEC source: 0000950170-25-024895 · ownership.xml · nonDerivative · entry 2 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,164 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 2,248 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-024895 · ownership.xml · nonDerivative · entry 1 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 17:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 5,444 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074410 · ownership.xml · nonDerivative · entry 1 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,088 F1 · shares: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| June 13, 2024 Filed Dec 20, 2024 16:30 UTC Amendment | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 5,939 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-139096 · ownership.xml · nonDerivative · entry 1 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,583 F1 · shares: On June 17, 2024, the Reporting Person filed a Form 4 which, due to an administrative error, incorrectly reported that the Reporting person had been awarded 5,444 shares of restricted stock pursuant to the Company's non-employee director compensation policy. This amendment to Form 4 is being filed to reflect the correct amount of shares awarded pursuant to the policy. Read SEC document |
| May 01, 2024 Filed May 2, 2024 19:00 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 67 | $60.15 | $4,030.05 |
DisclosureSEC source: 0000950170-24-052393 · ownership.xml · nonDerivative · entry 2 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,644 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain performance stock units. Read SEC document |
| April 30, 2024 Filed May 2, 2024 19:00 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 218 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-052393 · ownership.xml · nonDerivative · entry 1 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,711 F1 · shares: Represents additional shares of common stock received upon settlement of a performance share unit award on April 30, 2024. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 19:59 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 663 | $59.78 | $39,634.14 |
DisclosureSEC source: 0001209191-24-003919 · doc4.xml · nonDerivative · entry 2 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,493 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain performance stock units. Read SEC document |
| February 21, 2024 Filed Feb 22, 2024 19:38 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 706 | $61.50 | $43,419.00 |
DisclosureSEC source: 0001209191-24-003868 · doc4.xml · nonDerivative · entry 2 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,122 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 19:59 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 2,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-003919 · doc4.xml · nonDerivative · entry 1 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,156 F1 · shares: Represents shares of common stock received upon settlement of a performance share unit award on February 21, 2024. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 19:38 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 2,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-003868 · doc4.xml · derivative · entry 4 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Represents a restricted stock unit award granted on February 19, 2021 that vests in four equal annual installments from the grant date. F4 · derivative.expiration_date: Represents a restricted stock unit award granted on February 19, 2021 that vests in four equal annual installments from the grant date. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 19:38 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 2,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-003868 · doc4.xml · nonDerivative · entry 1 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 18:23 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 1,376 | $61.43 | $84,527.68 |
DisclosureSEC source: 0001209191-24-003464 · doc4.xml · nonDerivative · entry 2 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,580 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 18:23 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 3,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-003464 · doc4.xml · derivative · entry 4 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Represents a restricted stock unit award that fully vested on February 14, 2024. F4 · derivative.expiration_date: Represents a restricted stock unit award that fully vested on February 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 18:23 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 3,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-003464 · doc4.xml · nonDerivative · entry 1 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 16:16 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 6,209 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036269 · doc4.xml · nonDerivative · entry 1 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,984 F1 · shares: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 17:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 4,153 | $61.12 | $253,831.36 |
DisclosureSEC source: 0001209191-23-014251 · doc4.xml · nonDerivative · entry 3 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,775 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 27, 2023. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 17:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 3,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014251 · doc4.xml · derivative · entry 6 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,263 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award that partially vested on February 27, 2023. The restricted stock units vested in four equal annual installments beginning on February 26, 2020. F5 · derivative.expiration_date: Represents a restricted stock unit award that partially vested on February 27, 2023. The restricted stock units vested in four equal annual installments beginning on February 26, 2020. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 17:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 5,931 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014251 · doc4.xml · derivative · entry 5 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,931 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Represents a restricted stock unit award that vested on February 27, 2023. F4 · derivative.expiration_date: Represents a restricted stock unit award that vested on February 27, 2023. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 17:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 3,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014251 · doc4.xml · nonDerivative · entry 2 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 17:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 5,931 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014251 · doc4.xml · nonDerivative · entry 1 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 22, 2023 Filed Feb 23, 2023 16:22 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 1,007 | $62.72 | $63,159.04 |
DisclosureSEC source: 0001209191-23-012174 · doc4.xml · nonDerivative · entry 2 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,734 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 21, 2023. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 16:22 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 2,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012174 · doc4.xml · derivative · entry 4 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,495 Underlying: Common Stock · 2,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Represents a restricted stock unit award that partially vested on February 21, 2023. The restricted stock units vest in four equal annual installments beginning on February 19, 2022. F4 · derivative.expiration_date: Represents a restricted stock unit award that partially vested on February 21, 2023. The restricted stock units vest in four equal annual installments beginning on February 19, 2022. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 16:22 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 2,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012174 · doc4.xml · nonDerivative · entry 1 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 15, 2023 Filed Feb 16, 2023 17:09 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 1,821 | $65.59 | $119,439.39 |
DisclosureSEC source: 0001209191-23-010138 · doc4.xml · nonDerivative · entry 2 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,493 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 14, 2023. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 17:09 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 3,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010138 · doc4.xml · derivative · entry 4 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,972 Underlying: Common Stock · 3,972 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Represents a restricted stock unit award that partially vested on February 14, 2023. The restricted stock units vest in four equal annual installments beginning on February 14, 2021. F4 · derivative.expiration_date: Represents a restricted stock unit award that partially vested on February 14, 2023. The restricted stock units vest in four equal annual installments beginning on February 14, 2021. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 17:09 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 3,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010138 · doc4.xml · nonDerivative · entry 1 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:03 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 7,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001763 · doc4.xml · nonDerivative · entry 2 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,342 F2 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy and vest in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| May 02, 2022 Filed Jan 5, 2023 16:03 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 328 | $47.41 | $15,550.48 |
DisclosureSEC source: 0001209191-23-001763 · doc4.xml · nonDerivative · entry 1 COWARD D SCOTT · CIK 0001247296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,562 F1 · shares: Represents shares of common stock purchased through Employee Stock Purchase Plan. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 17:25 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 3,912 | $76.69 | $300,011.28 |
DisclosureSEC source: 0001209191-22-014936 · doc4.xml · nonDerivative · entry 3 COWARD D SCOTT · CIK 0001247296 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,234 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 28, 2022. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 20,428 shares, Mr. Coward also holds, in the aggregate, an additional 51,718 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 17:25 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 3,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014936 · doc4.xml · derivative · entry 6 COWARD D SCOTT · CIK 0001247296 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,262 Underlying: Common Stock · 3,263 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Represents a restricted stock unit award that partially vested on February 28, 2022. The restricted stock units vest in four equal annual installments beginning on February 26, 2020. F6 · derivative.expiration_date: Represents a restricted stock unit award that partially vested on February 28, 2022. The restricted stock units vest in four equal annual installments beginning on February 26, 2020. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 17:25 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 5,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014936 · doc4.xml · derivative · entry 5 COWARD D SCOTT · CIK 0001247296 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,025 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award that partially vested on February 28, 2022. The restricted stock units vest in four equal annual installments beginning on February 27, 2019. F5 · derivative.expiration_date: Represents a restricted stock unit award that partially vested on February 28, 2022. The restricted stock units vest in four equal annual installments beginning on February 27, 2019. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 17:25 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 3,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014936 · doc4.xml · nonDerivative · entry 2 COWARD D SCOTT · CIK 0001247296 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 17:25 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 5,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014936 · doc4.xml · nonDerivative · entry 1 COWARD D SCOTT · CIK 0001247296 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 18:42 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantRestricted Stock Units · Derivative | 5,931 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014341 · doc4.xml · derivative · entry 3 COWARD D SCOTT · CIK 0001247296 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,931 Underlying: Common Stock · 5,931 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: These restricted stock units vest in full on the first anniversary of the grant date. F3 · derivative.expiration_date: These restricted stock units vest in full on the first anniversary of the grant date. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 18:37 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 5,815 | $70.10 | $407,631.50 |
DisclosureSEC source: 0001209191-22-013329 · doc4.xml · nonDerivative · entry 2 COWARD D SCOTT · CIK 0001247296 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,858 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain performance stock units on February 23, 2022. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 16,052 shares, Mr. Coward also holds, in the aggregate, an additional 54,075 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 19:07 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 1,109 | $69.05 | $76,576.45 |
DisclosureSEC source: 0001209191-22-012818 · doc4.xml · nonDerivative · entry 2 COWARD D SCOTT · CIK 0001247296 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,926 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 22, 2022. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 9,120 shares, Mr. Coward also holds, in the aggregate, an additional 54,075 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 18:37 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionPerformance Stock Units · Derivative | 12,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013329 · doc4.xml · derivative · entry 4 COWARD D SCOTT · CIK 0001247296 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,747 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Performance Share Unit represents a right to receive one share of common stock. F5 · derivative.exercise_date: The PSU Award was subject to certain performance-based vesting requirements for the three-year period ending December 31, 2021. F5 · derivative.expiration_date: The PSU Award was subject to certain performance-based vesting requirements for the three-year period ending December 31, 2021. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 18:37 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 12,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013329 · doc4.xml · nonDerivative · entry 1 COWARD D SCOTT · CIK 0001247296 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon settlement of a performance share unit award ("PSU Award") on February 23, 2022 which is described further in Footnote 5 to this Form 4. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 19:07 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 2,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-012818 · doc4.xml · derivative · entry 4 COWARD D SCOTT · CIK 0001247296 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,744 Underlying: Common Stock · 2,247 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award that partially vested on February 22, 2022. The restricted stock units vest in four equal annual installments beginning on February 19, 2022. F5 · derivative.expiration_date: Represents a restricted stock unit award that partially vested on February 22, 2022. The restricted stock units vest in four equal annual installments beginning on February 19, 2022. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 19:07 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 2,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-012818 · doc4.xml · nonDerivative · entry 1 COWARD D SCOTT · CIK 0001247296 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 19:58 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 1,813 | $79.55 | $144,224.15 |
DisclosureSEC source: 0001209191-22-010368 · doc4.xml · nonDerivative · entry 3 COWARD D SCOTT · CIK 0001247296 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,788 F3 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 14, 2022. F4 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 7,982 shares, Mr. Coward also holds, in the aggregate, an additional 56,322 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.